Cargando…
Managing the multifaceted nature of type 2 diabetes using once‐weekly injectable GLP‐1 receptor agonist therapy
WHAT IS KNOWN AND OBJECTIVE: As a highly prevalent chronic condition associated with complications and high mortality rates, it is important for pharmacists to have a comprehensive understanding of the impact of type 2 diabetes (T2D) and available treatment options. The use of injectable glucagon‐li...
Autor principal: | Bzowyckyj, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540468/ https://www.ncbi.nlm.nih.gov/pubmed/32910488 http://dx.doi.org/10.1111/jcpt.13229 |
Ejemplares similares
-
Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao, Qing, et al.
Publicado: (2016) -
Safety and tolerability of once‐weekly GLP‐1 receptor agonists in type 2 diabetes
por: Trujillo, Jennifer
Publicado: (2020) -
Cardiovascular safety outcomes of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Goldman, Jennifer D.
Publicado: (2020) -
Glycaemic and non‐glycaemic efficacy of once‐weekly GLP‐1 receptor agonists in people with type 2 diabetes
por: Patel, Dhiren
Publicado: (2020) -
An overview of the once‐weekly GLP‐1 receptor agonists from the pharmacist’s perspective
por: Patel, Dhiren
Publicado: (2020)